Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Mimic human complexity in a Beat to revolutionize the drug development

Project description

Tuneable organ-on-a-chip technology for drug discovery

The organ-on-a-chip (OoC), a system containing miniaturised physiological tissues grown in microfluidic chips, has found numerous biomedical and drug discovery applications. The EU-funded uBeat project provides an innovative OoC technology known as BiomimX that applies tuneable mechanical stimulation onto 3D cell cultures. This technology has the potential to recapitulate native tissues and generate models of human disease. Additional advantages include the real-time evaluation of clinically relevant parameters and the high-throughput potential for drug screening. Researchers have already applied uBeat OoCs to test drugs causing cardiotoxicity, and plan to extend the versality of the technology in other drug development fields.

Objective

BiomimX Beating organs-on-chips (OoC) are in vitro miniaturized and living replica of human organs and diseases,
building upon cutting-edge technologies and human cells. Beating OoC provide a faithful replication of native human
physiology integrating miniaturized 3D cell culture techniques, mechanical stimulation (uBeat®) and electrical recording
capabilities (uSense). BiomimX’s proprietary key technology (uBeat®) supports 3D human cell cultures and integrates a
controlled and tunable mechanical stimulation system. uBeat® leads to the generation of mature and functional miniaturized
replication of human organs adequate to test compounds toxicity/functionality in a high-throughput fashion. Integration of
uSense allows real-time evaluation of clinically relevant parameters from the established beating models. BiomimX’s
Beating OoC represent a safer, more efficient and faster alternative to poorly predictable preclinical models to date available in
the drug discovery pipeline (DDP). BiomimX already demonstrated the validity of its Beating OoC models in two critical fields of
the drug discovery pipeline: uHeart (human beating heart-on-chip) has been applied as early predictor of drug functional
cardiotoxicity, uKnee (first in vitro model of human OA) has shown its predictive potential for the discovery of new targets for
an unmet pathology.
Also thanks to the contribution of Women TechEU programme, BiomimX aims at demonstrating the unprecedented potential of its disruptive innovation in reshaping the market of drug development, by i) boosting technological aspects (i.e. through an intensive industrialization process of BiomimX patented technologies) and ii) proving the versatility of its innovation and its capacity to adapt to a manifold of indications and market spaces. In line with the 3R principle, BiomimX final vision is to reduce and eventually replace animal experimentations within the next 15 years.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-CSA - HORIZON Coordination and Support Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIE-2021-SCALEUP-01

See all projects funded under this call

Coordinator

BIOMIMX SRL
Net EU contribution
€ 75 000,00
Address
VIALE DECUMANO 41
20157 MILANO
Italy
SME
Yes
Region
Nord-Ovest Lombardia Milano
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data